Key result
Calcific aortic valve disease was associated with significant changes in metabolic and protein profiles, identifying 229 differential metabolites and 549 differentially expressed proteins.
Why the study?
This study aimed to define changes in the metabolic and protein profiles of patients with calcific aortic valve disease.
What are the integrated proteomic and metabolomic profile differences in cardiac valves of patients with calcific aortic valve disease compared to controls?
Case-Control (n=48)
What are the integrated proteomic and metabolomic profile differences in cardiac valves of patients with calcific aortic valve disease compared to controls?
Integrated proteomic and metabolomic profiling of CAVD valves identified key dysregulated pathways and hub proteins (ENPP1, ABCA8, CAMK2D) that may serve as novel diagnostic or therapeutic targets.
Hypothesis-generating for CAVD targets; requires prospective validation before any clinical application.
Background This study aimed to define changes in the metabolic and protein profiles of patients with calcific aortic valve disease (CAVD). Methods and results We analyzed cardiac valve samples of patients with and without (control) CAVD ( n = 24 per group) using untargeted metabolomics and tandem mass tag-based quantitative proteomics. Significantly different metabolites and proteins between the CAVD and control groups were screened; then, functional enrichment was analyzed. We analyzed co-expressed differential metabolites and proteins, and constructed a metabolite-protein-pathway network. The expression of key proteins was validated using western blotting. Differential analysis identified 229 metabolites in CAVD among which, 2-aminophenol, hydroxykynurenine, erythritol, carnosine, and choline were the top five. Proteomic analysis identified 549 differentially expressed proteins in CAVD, most of which were localized in the nuclear, cytoplasmic, extracellular, and plasma membranes. Levels of selenium binding protein 1 (SELENBP1) positively correlated with multiple metabolites. Adenosine triphosphate-binding cassette transporters, starch and sucrose metabolism, hypoxia-inducible factor 1 (HIF-1) signaling, and purine metabolism were key pathways in the network. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), calcium 2+ /calmodulin-dependent protein kinase II delta (CAMK2D), and ATP binding cassette subfamily a member 8 (ABCA8) were identified as hub proteins in the metabolite-protein-pathway network as they interacted with ADP, glucose 6-phosphate, choline, and other proteins. Western blotting confirmed that ENPP1 was upregulated, whereas ABCA8 and CAMK2D were downregulated in CAVD samples. Conclusion The metabolic and protein profiles of cardiac valves from patients with CAVD significantly changed. The present findings provide a holistic view of the molecular mechanisms underlying CAVD that may lead to the development of novel diagnostic biomarkers and therapeutic targets to treat CAVD.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2022) conducted a case-control in Calcific aortic valve disease (n=48). Calcific aortic valve disease vs. Patients without CAVD (control) was evaluated on Differentially expressed metabolites and proteins. Calcific aortic valve disease was associated with significant changes in metabolic and protein profiles, identifying 229 differential metabolites and 549 differentially expressed proteins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: